Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Infection and Immunity
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Host Response and Inflammation

Bactericidal/Permeability-Increasing Protein Prevents Mucosal Damage in an Experimental Rat Model of Chronic Otitis Media with Effusion

Marja J. Nell, Henk K. Koerten, Jan J. Grote
Marja J. Nell
Department of Otorhinolaryngology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henk K. Koerten
Center for Electronmicroscopy, Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan J. Grote
Department of Otorhinolaryngology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/IAI.68.5.2992-2994.2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

In this study, the efficacy of bactericidal/permeability-increasing protein (BPI) was assessed in a rat model of chronic otitis media with effusion. BPI injection prevented disturbance of the mucociliary clearance system of the middle ear. Hence, it is postulated that BPI can be a new therapy for chronic otitis media with effusion.

Chronic otitis media with effusion (OME) is a frequent disease during childhood, and its complications and sequelae often persist into the adult years (7). Two important factors in the development of OME are obstruction or dysfunction of the eustachian tube and bacterial infection. In chronic OME, the majority of cases are caused by gram-negative bacteria (GNB), whereas in acute OME gram-positive bacteria are also frequently isolated (1). Lipopolysaccharide (LPS) is a component of GNB. LPS alone has been shown to induce mucosal inflammation with accumulation of effusion in the middle ears of chinchillas (2) and guinea pigs (14). Furthermore, LPS has been detected in human middle ear effusions (3), and the level of it was found to be significantly higher in children with chronic OME than in children with acute OME (13). Finally, LPS is also thought to be cytotoxic to ciliated epithelial cells (10).

We recently developed an animal model of chronic OME using a combination of eustachian tube obstruction (ETO) and LPS injection (12). This procedure induces an increase in secretory cells of the epithelium and degeneration of cilia, which results in a disturbance of the mucociliary clearance system (MCS) of the middle ear. Comparable mucosal changes have been observed in humans with chronic OME (9, 15). The MCS is considered to be an important defense system of the middle ear cavity, and disturbance of this system is suspected to be an important factor in the development of chronic OME.

Bactericidal/permeability-increasing protein (BPI), a 55-kDa cationic protein present in the granules of polymorphonuclear neutrophils (PMNs), is an antimicrobial protein that has been implicated in the host defensive response to GNB infection (5). In addition to being bactericidal against GNB, BPI binds to the highly conserved lipid A portion of LPS with high affinity and can inhibit its actions (11). Previous investigations have shown that a 21-kDa recombinant amino-terminal fragment of BPI (rBPI21) protects animals against the effects of GNB and LPS (6). Furthermore, in humans, rBPI21 appears to be safe and non-immunogenic and is in phase II/III clinical trials with apparent therapeutic benefit (4, 6, 8). In the present study, we aimed to assess the in vivo capacity of rBPI21 to prevent mucosal damage in chronic OME.

Induction of chronic OME.During anesthesia with nitrous oxide, the eustachian tube was reached by a ventral approach, medially to the posterior belly of the digastric muscle, and obstructed by plugging a small piece of Gelfoam (Upjohn Co.) into the tube. Moreover, a drop of tissue glue (Historesin; Braun, Melsungen, Germany) was used to keep the Gelfoam in the tube. In addition, 50 μl of LPS solution (2 μg/ml) in phosphate-buffered saline (PBS) prepared fromSalmonella typhimurium (L-6511; Sigma, Zwijndrecht, The Netherlands) was injected through the tympanic membrane. As a control, the other ear was injected with 50 μl of PBS.

After 1, 2, 4, and 12 weeks, the animals were killed with CO2 gas and subsequently decapitated. The middle ear was dissected from the skull, denuded of adhering tissues, and further processed for light microscopy (LM) and scanning electron microscopy (SEM). For LM the specimens were fixed, decalcified, subsequently dehydrated in a graded series of ethanol, and embedded in glycol methacrylate (JB4; Brunschwig Chemie, Amsterdam, The Netherlands). Sections were stained with toluidine blue for histological studies and with alcian blue–periodic acid-Schiff for glycogen histochemistry. Specimens for SEM analysis were fixed, dehydrated in graded series of ethanol, and critical-point dried with liquid CO2. The distribution of the epithelial cells was studied with a Philips 525M scanning electron microscope after specimens were mounted and coated with gold in a Balzers MED010 Sputtercoater. The absolute numbers of ciliated and secretory cells were counted in duplicate in each ear in two standardized areas of the same size in the tympanic orifice. Statistical comparisons were made by the Tukey highest significant difference (HSD) test, with P < 0.05 considered significant, using the Statistical Package for the Social Sciences.

Histopathological findings.By LM and SEM, control middle ears remained apparently normal during the whole period. The hypotympanum of the middle ear consisted of thin, one-layered squamous epithelium, containing very few ciliated cells (Fig.1A). In the tympanic orifice of the eustachian tube, a more pseudostratified, cuboidal, or cylindrical epithelium was observed, which contained an abundant number of ciliated cells and few secretory cells (Fig. 2A). This part represents the mucociliary clearance system of the middle ear.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Light micrographs of the hypotympanum at 12 weeks after PBS injection (A), ETO and LPS injection (B), and ETO plus LPS with rBPI21 injection after 2 days (C). OME induction caused thickening of the mucosa (between arrows) and infiltration of inflammatory cells (arrowheads). This was not observed after rBPI21 injection. Magnification, ×200; bar, 10 μm.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

SEM of the tympanic orifice at 12 weeks after (A) PBS injection, (B) ETO and LPS injection, and (C) ETO plus LPS with rBPI21 injection after 2 days. Abundant goblet cells (arrows) and ciliated cells are present. OME induction caused degeneration of cilia and swollen epithelial cells (asterisks). This was not observed after rBPI21 injection, and the cilia had a normal appearance. Magnification, ×1,250; bar, 10 μm.

The combination of ETO and LPS injection induced thickening of the middle ear mucosa due to vasodilatation, edema, and infiltration by PMNs, macrophages, and lymphocytes in the hypotympanum (Fig. 1B). Compared with control ears after PBS injection, significantly fewer ciliated cells were observed in the tympanic orifice of ETO plus LPS-treated ears (Fig. 3), and severely swollen squamous epithelium was observed by SEM after 3 months (Fig.2B). Furthermore, a significant increase in secretory cells was observed (Fig. 4). It is clear from these histopathological findings that the MCS was disturbed. Due to hyperproliferation of secretory cells, increased mucus production induced mucoid middle ear effusion. Dysfunction or degeneration of ciliated epithelial cells was responsible for accumulation of surplus fluid in the tympanic cavity. Therefore, clearance of the middle ear was seriously impaired.

Fig. 3.
  • Open in new tab
  • Download powerpoint
Fig. 3.

Numbers of ciliated cells ± standard deviations (n = 4) counted in the tympanic orifice after PBS injection, ETO with LPS injection (ETO+LPS), and ETO plus LPS with rBPI21 injection after 2 days (ETO+LPS+BPI). Statistical comparisons were made by the Tukey HSD test. ∗, significantly different from PBS; ∗∗, significantly different from ETO+LPS of the same week. Injection of rBPI21 after 2 days prevented the decrease in the numbers of ciliated cells caused by OME induction.

Treatment with BPI.Two days after induction of chronic OME, 50 μl of 2-mg/ml rBPI21, a recombinant 21-kDa amino-terminal fragment of BPI (Xoma LLC., Berkeley, Calif.), was injected into the middle ear cavity. To ensure complete neutralization of LPS, an amount of rBPI21 equal to 1,000 times the LPS concentration was used (11). It was decided to inject the BPI after 2 days to investigate the effect of BPI during an acute inflammation reaction for prevention of chronic OME. Injection of BPI prevented the thickening of the middle ear mucosa in the hypotympanum seen after ETO in combination with LPS injection. No infiltration of inflammatory cells in the subepithelial layer was observed (Fig. 1C). In the tympanic orifice, an abundance of ciliated cells were present and no significant increase in secretory cells was seen (Fig. 3 and 4). BPI prevented the induction of mucosal changes in the rat middle ear (Fig. 2C) seen after ETO and LPS injection.

Fig. 4.
  • Open in new tab
  • Download powerpoint
Fig. 4.

Numbers of goblet cells ± standard deviations (n = 4) counted in the tympanic orifice after PBS injection, ETO with LPS injection (ETO+LPS), and ETO plus LPS with rBPI21 injection after 2 days (ETO+LPS+BPI). Statistical comparisons were made by the Tukey HSD test. ∗, significantly different from PBS; ∗∗, significantly different from ETO+LPS of the same week. Application of rBPI21 after OME induction significantly inhibited the increase in the numbers of goblet cells.

In cases of ear infections complicated by ETO, bacterial products, including LPS, can be trapped in the middle ear. The uncleared bacterial products can perpetuate the inflammation, even after viable bacteria have been killed with antibiotics, further compromising the MCS. In these situations, continued treatment with antibiotics is not likely to be effective. Moreover, widespread use of antibiotics is unwise due to growing bacterial resistance. Therefore, agents that can inhibit the inflammatory activity of LPS could help break the inflammatory cycle and reestablish an effective MCS. Our results suggest that treatment with rBPI21 is a potential therapy for preventing the occurrence of chronic OME.

ACKNOWLEDGMENTS

This work was supported by the Netherlands Organization for Scientific Research, Technology Foundation, grant LGN 33.3249, and partly by a grant from the Heinsius Houbolt Foundation.

Notes

Editor: J. D. Clements

FOOTNOTES

    • Received 7 September 1999.
    • Returned for modification 15 November 1999.
    • Accepted 27 January 2000.
  • Copyright © 2000 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Bluestone C. D.,
    2. Stephenson J. S.,
    3. Martin L. M.
    Ten-year review of otitis media pathogenesis.Pediatr. Infect. Dis. J.111992S7S11
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. DeMaria T. F.,
    2. Briggs B. R.,
    3. Lim D. J.,
    4. Okazaki N.
    Experimental otitis media with effusion following middle ear inoculation of nonviable H. influenzae.Ann. Otol. Rhinol. Laryngol.9319845256
    OpenUrlPubMedWeb of Science
  3. 3.↵
    1. DeMaria T. F.,
    2. Prior R. B.,
    3. Briggs B. R.,
    4. Lim D. J.,
    5. Birck H. G.
    Endotoxin in middle-ear effusions from patients with chronic otitis media with effusion.J. Clin. Microbiol.2019841517
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Demetriades D.,
    2. Smith S.,
    3. Jacobson L. E.,
    4. Moncure M.,
    5. Minei J.,
    6. Nelson B. J.,
    7. Scannon P. J.
    Bactericidal/permeability-increasing protein (rBPI21) in patients with hemorrhage due to trauma: results of a multicenter phase II clinical trial.J. Trauma Inj. Infect. Crit. Care461999667677
    OpenUrlCrossRef
  5. 5.↵
    1. Elsbach P.,
    2. Weiss J.
    The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against gram-negative bacteria and lipopolysaccharide.Immunobiology1871993417429
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Elsbach P.,
    2. Weiss J.
    Role of the bactericidal/permeability-increasing protein in host defence.Curr. Opin. Immunol.1019984549
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Giebink G. S.
    Otitis media update: pathogenesis and treatment.Ann. Otol. Rhinol. Laryngol.10119922123
    OpenUrl
  8. 8.↵
    1. Giroir B. P.,
    2. Quint P. A.,
    3. Barton P.,
    4. Kirsch E. A.,
    5. Kitchen L.,
    6. Goldstein B.,
    7. Nelson B. J.,
    8. Wedel N. I.,
    9. Carroll S. F.,
    10. Scannon P. J.
    Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis.Lancet350199714391443
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Hentzer E.
    Ultrastructure of the middle ear mucosa in secretory otitis media. II. Mucous effusion.Acta Otolaryngol.731972467475
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Johnson A. P.,
    2. Inzana T. J.
    Loss of ciliary activity in organ cultures of rat trachea treated with lipo-oligosaccharide from Haemophilus influenzae.J. Med. Microbiol.221986265268
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Marra M. N.,
    2. Thornton M. B.,
    3. Snable J. L.,
    4. Wilde C. G.,
    5. Scott R. W.
    Endotoxin-binding and neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5.Crit. Care Med.221994559565
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Nell M. J.,
    2. Grote J. J.
    Structural changes in the rat middle ear mucosa due to endotoxin and eustachian tube obstruction.Eur. Arch. Otorhinolaryngol.2561999167172
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Nell M. J.,
    2. Grote J. J.
    Endotoxin and TNF-alpha in middle ear effusions: in relation with upper airway infection.Laryngoscope109199918151819
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Nonomura N.,
    2. Nakano Y.,
    3. Satoh Y.,
    4. Fujioka O.,
    5. Niijima H.,
    6. Fujita M.
    Otitis media with effusion following inoculation of Haemophilus influenzae type b endotoxin.Arch. Otorhinolaryngol.24319863135
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Shimooka R.,
    2. Yajin K.,
    3. Harada Y.
    SEM studies of the inflammatory changes of the middle ear mucosa.Auris Nasus Larynx1019837986
    OpenUrlPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
Bactericidal/Permeability-Increasing Protein Prevents Mucosal Damage in an Experimental Rat Model of Chronic Otitis Media with Effusion
Marja J. Nell, Henk K. Koerten, Jan J. Grote
Infection and Immunity May 2000, 68 (5) 2992-2994; DOI: 10.1128/IAI.68.5.2992-2994.2000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Infection and Immunity article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Bactericidal/Permeability-Increasing Protein Prevents Mucosal Damage in an Experimental Rat Model of Chronic Otitis Media with Effusion
(Your Name) has forwarded a page to you from Infection and Immunity
(Your Name) thought you would be interested in this article in Infection and Immunity.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Bactericidal/Permeability-Increasing Protein Prevents Mucosal Damage in an Experimental Rat Model of Chronic Otitis Media with Effusion
Marja J. Nell, Henk K. Koerten, Jan J. Grote
Infection and Immunity May 2000, 68 (5) 2992-2994; DOI: 10.1128/IAI.68.5.2992-2994.2000
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • Notes
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Infective Agents
Blood Proteins
membrane proteins
Otitis Media with Effusion

Related Articles

Cited By...

About

  • About IAI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #IAIjournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0019-9567; Online ISSN: 1098-5522